Immunomodulatory drugs (IMiDs) in multiple myeloma: mechanism of action and clinical implications
Immunomodulatory drugs (IMiDs) are a class of drugs, derived from the teratogenic compound thalidomide, that have made a major impact on treatment of many diseases, from multiple myeloma to assorted inflammatory diseases. From its dark beginnings as a teratogenic agent that caused phocomelia in newb...
Main Author: | Xu, Mengni |
---|---|
Language: | en_US |
Published: |
2017
|
Subjects: | |
Online Access: | https://hdl.handle.net/2144/24015 |
Similar Items
-
Central neurotoxicity of immunomodulatory drugs in multiple myeloma
by: Urmeel H. Patel, et al.
Published: (2015-03-01) -
Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01) -
Next-generation immunomodulatory drugs in multiple myeloma
by: Anna Suska, et al.
Published: (2019-12-01) -
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
by: Marco Cippitelli, et al.
Published: (2021-01-01) -
Thalidomide and its analogues in the treatment of Multiple Myeloma
by: Latif Tahir, et al.
Published: (2012-09-01)